Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

StockNews.com

Relay Therapeutics (RLAY) vs. Perrigo Company (PRGO): Which Pharma Stock Holds Better Upside Potential?

The pharmaceutical industry’s prospects look bright, fueled by a rapidly aging population, the rising prevalence of chronic diseases, consistent R&D efforts backed by government funding, and digital transformation. Pharma stocks Relay Therapeutics (RLAY) and Perrigo Company (PRGO) should benefit from the industry tailwinds. But let’s find out which stock holds…

StockNews.com

Spurious drugs, worth about ₹1 crore supplied to A.P.

DCA officials in Andhra Pradesh have identified spurious drugs worth over ₹1 crore in Visakhapatnam, Tirupati, Kadapa, Vijayawada and other cities.

The Hindu

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugs Control Administration unearths spurious medicine racket in Vijayawada

Drugs Control Administration busts spurious drug racket in Vijayawada. Fake drugs falsely labelled as products of reputed pharma companies were found. These drugs can cause severe health damage and even death. FIR registered against two persons under IPC sections. 24 samples sent to Drug Control Lab, 6 declared sub-standard. Original…

The Hindu

Is Flora Growth (FLGC) a Good Agriculture Stock Buy Right Now?

Flora Growth (FLGC) entered a new partnership recently to grow its presence in Europe. Moreover, as the European Union moves toward de-scheduling narcotics, is this the right time to scoop up FLGC shares? Read on.

StockNews.com

Experts question Ministry on reversal of provisions targeting inappropriate AYUSH advertisements

Previously the Ministry of AYUSH signed an MoU with ASCI for two years to undertake monitoring of AYUSH-related advertisements.

The Hindu

Drugs regulator issues alert after pharma firm Abbott India recalls antacid syrup Digene Gel

The public notice issued by the apex drug controller on its website said: “The impugned product may be unsafe and its use may result in adverse reaction.”

The Hindu

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks Smart Money Is Following in September

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

StockNews.com

Hundreds of women taking legal action against Bayer over Essure sterilisation device

The Essure device reportedly left many women suffering ‘excrutiating pain’ and other symptoms

Evening Standard

Hundreds of women left in ‘excruciating pain’ from contraceptive coil launch legal action

‘I was in pain pretty much every day. And then I started having periods that lasted 28-30 days at a time,’ woman says

The Independent UK

Two hundred UK women can take legal action over Essure contraceptive device

Group claim able to proceed against maker Bayer after women said implant caused pain, BBC reports

The Guardian - UK

Wegovy maker Novo Nordisk becomes Europe’s most valuable firm

Launch of weight-loss drug in UK helps Danish firm to market value of $428bn

The Guardian - UK

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

StockNews.com

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks to Consider Prescribing to for Quality

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given the solid long-term prospects of the industry, investors should consider buying quality stocks, Johnson & Johnson (JNJ), AstraZeneca (AZN), and Dr. Reddy’s Laboratories (RDY). Read on.

The Independent UK

Medicines360’s long and winding, $82 million road to create and distribute $50 birth control

Drugs and medical devices rarely come from the nonprofit world

StockNews.com

3 Brilliant Biotech Stocks to Buy for Your Portfolio

The biotech industry is flourishing on the backs of positive clinical trials and new developments. Thus, it could be beneficial to add fundamentally robust biotech stocks BioMarin Pharmaceutical (BMRN), Equillium (EQ), and Organogenesis Holdings (ORGO) to your portfolios. Read more….

Salon

About the new drug pricing negotiations

The first eligible drugs treat diabetes, blood clots, blood cancers, arthritis and heart disease

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Sun-Times

5 things consumers need to know about Medicare’s new drug-pricing negotiations, how they’ll affect you

This could help people whose Medicare drug plans require big copayments. But the main relief will come from part of the Inflation Reduction Act that caps drug spending by Medicare recipients at $2,000 a year starting in 2025.

Kiplinger

Medicare Lists First 10 Drugs for Talks On Lowering Your Costs

New prices for Medicare Part D drugs on list expected in 2026.

StockNews.com

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

The Guardian - UK

Staffordshire-based Instem bought by private equity group for £203m

Instem is second UK life sciences company this week to be snapped up by a foreign buyer

The Independent UK

Biden touts Medicare negotiating drug prices: ‘Today is the start of a new deal for patients’

Announcement comes as Medicare names the drugs it will begin negotiations for prices

The Independent UK

3M agrees to multi-billion dollar settlement in earplug lawsuits from U.S. service members

Chemical and consumer product manufacturer 3M has agreed to pay $6 billion to settle numerous lawsuits from U.S. service members who say they experienced hearing loss or other serious injuries from using earplugs made by the company

StockNews.com

3 Best Biotech Stocks for Health and Wealth

With medical innovations and technological breakthroughs rapidly transforming the healthcare landscape, biotech stocks have garnered unprecedented attention in the investment community. Thus, fundamentally robust stocks like Incyte Corp. (INCY), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN) could contribute to the health and wealth of your portfolios. Read more….

1 … 41 42 43 44

People

Joe Biden

67,095 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.